Article

Health System Pilots See Lackluster Bundled Payment Results

Three health care systems have reported that efforts to bundle payments for specific episodes of care have proven not quite as efficient as they initially thought the program would be. The systems have been attempting to implement bundling payments for three years without a single contract even being entered into.

Read the full story here: http://www.fiercehealthfinance.com/story/healthcare-systems-find-huge-obstacles-bundled-payments/2011-11-08

Source: FierceHealthFinance

Related Videos
AAD 2025 Recap
Dr Xin Hu
3 experts are featured in this series.
1 expert is featured in this series.
3 experts are featured in this series.
Brittany Craiglow, MD, FAAD
Lawrence Eichenfield, MD, FAAD
Related Content
John Brandsema, MD
March 14th 2025

Enhancing SMA Care Through Early Diagnosis and Family Education

Steve Brandsema, MD Skylar Jeremias
A multidisciplinary approach, early diagnosis, and comprehensive caregiver education are crucial in effectively managing spinal muscular atrophy (SMA).
Managed Care Cast Logo
February 25th 2025

Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care

Pearl Steinzor Arthur L. Jenkins III, MD, FACS
On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
In patients with MDS and AML, the researchers found impaired neutrophil subset distribution compared with healthy individuals. | Image credit: keetazalay - stock.adobe.com
March 14th 2025

Neutrophil Subset Changes Give Insight Into First Mechanisms of MDS, AML

Rose McNulty
The new findings are the first to describe distributions and perturbations of low-density granulocyte and normal-density neutrophil subsets in myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and idiopathic cytopenia of unknown significance.
managed care cast logo
February 18th 2025

Varied Access: The Pharmacogenetic Testing Coverage Divide

Brooke McCormick Jai N. Patel, PharmD
On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Congenital heart disease | Image Credit: © ibreakstock-stock.adobe.com
March 14th 2025

PAH Treatment Benefits Extend to Patients With Repaired Congenital Heart Disease

Maggie L. Shaw
Historical data show the prevalence of pulmonary arterial hypertension (PAH) in adult patients with congenital heart disease ranges from 4% to 28%, according to studies from the US and Europe—and that the prevalence of these comorbid condition is on the rise.
Patients with R/R transformed DLBCL have modest 4-year event free and overall survival rates under 50%, making disease management a persistent challenge | SuriyaPhoto - stock.adobe.com
March 14th 2025

Atezolizumab, Immunogenic Chemotherapy Combination Shows Promise for DLBCL Treatment

Kyle Munz
An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and oxaliplatin (eloxatin; GemOx; R-GemOx+Atezo) could be a well-tolerated and effective treatment option in non-Hodgkin lymphoma.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo